Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
26 Juli 2023 - 1:30PM
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage
biotechnology company developing novel molecular glue degrader
(MGD)-based medicines, today announced the appointment of Anthony
M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a
highly accomplished drug discovery leader in the field of
autoimmune and inflammatory diseases.
”Dr. Manning brings extensive knowledge and experience in the
field of immunology and inflammation to our Board of Directors, and
we’re delighted to have him on our team,” said Markus Warmuth,
M.D., CEO of Monte Rosa. ”Tony’s experience developing multiple
first-in-class therapeutics for the treatment of immune-driven
diseases will be invaluable, particularly as our VAV1 program for
autoimmune diseases approaches the clinic, followed closely by our
NEK7 program for inflammatory diseases. We are proud to pioneer the
development of MGDs beyond oncology and in particular, in the areas
of immune and inflammatory conditions. With the team we’ve
assembled and leveraging the power of our QuEEN™ platform to
discover highly selective MGDs of key drivers of a variety of
crucial immune cell pathways, we are confident we can help a broad
group of patients with high unmet medical needs.”
Dr. Manning serves as a Board Director for Palatin Technologies,
Founder and Chair of the non-profit Institute for Biomedical
Entrepreneurship, and Scientific Advisor for several companies.
Most recently, Dr. Manning was Chief Scientific Officer at Momenta
Pharmaceuticals, where he built a pipeline of first-in-class
therapeutics for the treatment of autoantibody-driven diseases.
Momenta was acquired by Johnson & Johnson Corporation in 2020
for $6.5 billion. Prior to Momenta, Dr. Manning led research and
drug discovery efforts at Roche Pharmaceuticals, Pharmacia Corp.,
Biogen Idec, and several early-stage biotechnology companies. Dr.
Manning has contributed more than 120 scientific publications and
patents in the fields of autoimmune diseases, novel therapeutics,
and drug discovery.
“The ability to eliminate immune targets previously considered
undruggable, like VAV1, affords Monte Rosa an incredible advantage,
particularly when you consider the incredible specificity of
degradation demonstrated by their preclinical data,” said Dr.
Manning. “I am excited to support Monte Rosa Therapeutics on its
path to become the first company to progress the concept of
molecular glue-based protein degradation into the immunology and
inflammation field, and think the team and company are uniquely
positioned to do so. I look forward to working with the Board and
leadership team as they advance the company’s pipeline and bring
differentiated and transformational MGD-based therapies to
patients.”
About Monte RosaMonte Rosa Therapeutics is a
biotechnology company developing novel molecular glue degrader
(MGD) medicines for patients with serious diseases such as
oncology, autoimmune, and inflammatory diseases. MGDs are small
molecule protein degraders that employ the body’s natural
mechanisms to selectively eliminate therapeutically relevant
proteins. The company’s QuEEN™ (Quantitative and Engineered
Elimination of Neosubstrates) platform enables it to rapidly
identify protein targets and design highly selective degraders by
combining diverse libraries of proprietary MGDs with in-house
proteomics, structural biology, AI/machine learning, and
computational chemistry capabilities. For more information,
visit www.monterosatx.com.
Forward-Looking StatementsThis communication
includes express and implied “forward-looking statements,”
including forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward looking
statements include all statements that are not historical facts,
and in some cases, can be identified by terms such as “may,”
“might,” “will,” “could,” “would,” “should,” “expect,” “intend,”
“plan,” “objective,” “anticipate,” “believe,” “estimate,”
“predict,” “potential,” “continue,” “ongoing,” or the negative of
these terms, or other comparable terminology intended to identify
statements about the future. Forward-looking statements contained
herein include, but are not limited to, statements about our
product development activities, including expectations around the
advancement of our pipeline and the various products therein, their
therapeutic potential and the anticipated contribution of the
members of our board of directors, specifically Dr. Manning, and
our executives to our operations and progress. By their nature,
these statements are subject to numerous risks and uncertainties,
including those risks and uncertainties set forth in our most
recent Annual Report on Form 10-K for the year ended December 31,
2022 filed with the US Securities and Exchange Commission, and any
subsequent filings, that could cause actual results, performance or
achievement to differ materially and adversely from those
anticipated or implied in the statements. You should not rely upon
forward looking statements as predictions of future events.
Although our management believes that the expectations reflected in
our statements are reasonable, we cannot guarantee that the future
results, performance or events and circumstances described in the
forward-looking statements will be achieved or occur. Recipients
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date such statements are
made and should not be construed as statements of fact. We
undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, any future
presentations or otherwise, except as required by applicable
law.
ContactsInvestorsShai Biran
Monte Rosa Therapeutics ir@monterosatx.com
MediaCory Tromblee Scient Public
Relationsmedia@monterosatx.com
Monte Rosa Therapeutics (NASDAQ:GLUE)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Monte Rosa Therapeutics (NASDAQ:GLUE)
Historical Stock Chart
Von Mai 2023 bis Mai 2024